SCHEDULE: Innoviva Increases Stake in Armata via $25M Loan

Innoviva, Inc. has expanded its financial commitment to Armata Pharmaceuticals through a new $25 million secured credit agreement.

Summary

• Innoviva, Inc. and its subsidiary, Innoviva Strategic Opportunities LLC, entered into a $25 million credit agreement with Armata Pharmaceuticals on May 12, 2026.
• The reporting persons now beneficially own approximately 82.7% of Armata Pharmaceuticals' outstanding common stock.
• The total beneficial ownership includes 25,076,769 shares of common stock, 10,653,847 shares issuable via warrants, and 19,736,843 shares issuable upon conversion of a loan.
• The new credit facility carries an interest rate of 14.00% per annum and matures on January 11, 2029.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it provides necessary liquidity to the issuer, the high cost of debt and increased concentration of ownership reflect the ongoing financial challenges typical of early-stage biotech firms.

Positives

• Strengthened financial position for Armata Pharmaceuticals through secured debt financing.
• Continued long-term support from a major shareholder, Innoviva, Inc.

Negatives

• High interest rate of 14.00% on the new $25 million credit facility indicates significant cost of capital.
• Increased concentration of ownership by Innoviva, potentially limiting minority shareholder influence.

Risks

• High debt burden for Armata Pharmaceuticals given the 14% interest rate.
• Potential for further dilution of existing shareholders if warrants and convertible loans are exercised.
• Reliance on a single major shareholder for liquidity.

Future Outlook

The filing does not provide specific operational guidance but establishes a long-term debt maturity date of January 11, 2029, for the new credit facility.

Management Comments

• Pavel Raifeld, CEO of Innoviva, certified the accuracy of the beneficial ownership and transaction details.

Industry Context

StockSavvy.ai notes that this transaction reflects a common trend in the biotech sector where major institutional investors provide 'lifeline' financing to portfolio companies to sustain R&D operations, often at high interest rates due to the speculative nature of the underlying assets.

Comparison to Industry Standards

• The 14% interest rate is consistent with high-risk, venture-style debt financing for clinical-stage pharmaceutical companies.
• An 82.7% ownership stake represents a near-total control position, which is common for parent-subsidiary relationships in the biotech incubator model.

Related Party Transactions

• The credit agreement is between Armata Pharmaceuticals and Innoviva Sub, a wholly-owned subsidiary of Innoviva, Inc., which is a major shareholder.

Stakeholder Impact

• Shareholders face increased dilution risk from convertible debt and warrants.
• Creditors may be impacted by the priority of the new secured debt.

Next Steps

• Ongoing monitoring of Armata Pharmaceuticals' debt service obligations.
• Potential future conversion of debt or exercise of warrants by Innoviva.

Key Dates

Recommendation

The high interest rate and significant debt load suggest financial strain, but the continued support from a major shareholder provides a floor for liquidity. Investors should wait for further clinical trial results before increasing exposure.

Keywords

Armata Pharmaceuticals, Innoviva, Schedule 13D, Biotech, Credit Agreement, Debt Financing, Beneficial Ownership